Evotec
- Market cap
- 572.18M
- P/E (TTM)i
- -2.59
- P/Bi
- 0.77
- EPSi
- -0.33
- Div yieldi
- 0.00%
- 52W posi
- 4%
Anonymous reader poll. Unscientific, not investment advice.
About Evotec
Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the Shared R&D and Just–Evotec Biologics segments. The Shared R&D segment includes drug discovery and development services and solutions. The Just–Evotec Biologics segment provides services related to designing, discovering, developing, and manufacturing of modern biotherapeutics. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, Charles Weissmann, and Nobel Laureate on December 8, 1993 and is headquartered in Hamburg, Germany.
- Founded
- 1998
- CEO
- Mr. Christian Wojczewski, PhD
- Employees
- 4,553
- Headquarters
- Hamburg, Hamburg, Germany
- Fiscal year end
- 12-31
- Website
- evotec.com
Company profile
- Exchange
- US
- Symbol
- EVO
- Market-cap rank
- #3659
- Listing date
- 2021-11-04
- Market cap
- 572.18M
- Float cap
- 436.29M
- Shares out
- 355.39M
- Float shares
- 270.99M
Sectors & themes
Quote time 2026-10-08 08:57:43 · For reference only, not investment advice and not tailored to your situation.